On June 23, 2025，Professor Peter Fasching from University Hospital Erlangen in Germany was specially invited by the Cancer Center of the First Affiliated Hospital (FAH) of Xi’an Jiaotong University (XJTU) to conduct international consultations on challenging breast cancer cases and engage in academic exchanges.

Professor Fasching serves as Associate Professor of Translational Gynecologic Oncology at both University Hospital Erlangen and the Erlangen–EMN Comprehensive Cancer Center. His research focuses on big data , statistical modeling, genomics, and systems biology.

Liang Peng, Deputy Director of the Quality Control Office, Department of Medical Affairs, delivered a welcome speech. He expressed the hope that “China Tour of International Experts on Standardized Diagnosis and Treatment of Breast Cancer” event would serve as a valuable opportunity to exchange cutting-edge international concepts and technologies, and to jointly advance the standard of breast cancer diagnosis and treatment.

Following the remarks, Director Yang Jin and Director Ren Yu jointly presented Professor Peter Fasching with an Honorary Certificate as an International Remote Consultation Expert for Challenging Cases.

At the meeting, Professor Peter Fasching delivered a keynote presentation titled “Efficacy and Mechanisms of Progression in Patients with HR-Positive, HER2-Negative Early-Stage Breast Cancer”. He introduced the issue of endocrine therapy resistance in breast cancer, outlined the latest research advances in the use of CDK4/6 inhibitors in breast cancer treatment, and shared the design and results of the NATALEE clinical research. He also discussed treatment strategies tailored for elderly breast cancer patients through case-based exchanges. Experts at the meeting engaged in in-depth discussions on related topics.

Deputy Director Zhang Huimin introduced the development of the breast disease specialty at FAH, while Dr. Wang Fan from the Phase I Clinical Trial Center gave an overview of the progress of our Cancer Center’s MDT program and the Phase I Clinical Trial Research Center.

During the MDT case discussion session, Dr. Yang Jiao from the Department of Oncology presented a challenging case involving a young patient with highly aggressive, HR-positive, HER2-negative advanced breast cancer. Professor Peter Fasching held in-depth discussions with the MDT experts on a range of topics, such as resistance to CDK4/6 inhibitors, breast cancer-related genetic testing, the application of novel ADCs, and the role of local therapy in advanced breast cancer. Based on the patient's specific clinical presentation, he provided personalized diagnostic and treatment recommendations.

Following the discussion, Dr. Wang Bin from the Department of Breast Surgery performed a demonstration of an endoscopic breast surgery.